Members
Sanofi Achieves Top Three Ranking in the 2024 Access to Medicine Index
The French South African Chamber of Commerce and Industry (FSACCI) celebrates the remarkable achievement of platinum member Sanofi, which has secured 3rd place in the 2024 Access to Medicine Index. This recognition highlights Sanofi’s leadership in Governance of Access, as well as its strong performance in Research & Development and Product Delivery, setting a benchmark for best practices in inclusive business models aimed at improving access to medicine in low- and middle-income countries (LMICs).
Key Highlights of Sanofi’s Performance
Sanofi’s inclusive business model has demonstrated excellence in improving access to essential healthcare products in LMICs. The company has earned accolades for:
-
Robust access plans across its late-stage projects.
-
The Global Health Unit (GHU) initiative, which has increased access to 30 products in 40 countries with the highest unmet medical needs.
-
Expanding access to essential medicines like insulin and preventative treatments for respiratory conditions in infants.
Opportunities for Future Progress
Sanofi continues to demonstrate its commitment to equitable healthcare but has significant opportunities to further enhance its impact:
-
Broadening Access Plans:
Sanofi is encouraged to improve the quality and expand the geographic reach of its access plans. For instance, its Phase III intranasal respiratory syncytial virus vaccine (SP0125) could benefit from broader coverage beyond the nine countries currently in scope.
- Enhancing Transparency:
Regular public reporting on the progress and outcomes of its inclusive business model will strengthen transparency and partnerships. Detailed country-level data and patient reach figures could provide deeper insights into the impact of specific initiatives.
- Scaling Insulin Access:
Building on the success of its Impact® insulin glargine supply strategy in 10 low-income countries, Sanofi can expand this model to other analogue insulins such as Admelog® and Suliqua™.
- Widening Access to Nirsevimab (Beyfortus®):
With its innovative preventative medicine for respiratory syncytial virus (RSV) complications in newborns, Sanofi can increase access by focusing on expanded registration, equitable access strategies, and voluntary licensing.
Driving Positive Change
Sanofi’s recognition in the 2024 Access to Medicine Index underscores its commitment to bridging healthcare gaps in LMICs. By building on its strong foundation and pursuing new opportunities, Sanofi can continue to set global standards for access and equity in healthcare.
Read the full report below:
